#ESMO26 两种 ADC + IO 能否在一线转移性尿路上皮癌中进一步提高缓解率？
🚨TROPHY-U-01 第 7 队列，评估 sacituzumab govitecan + enfortumab vedotin + zimberelimab（N=21）。
🔹 ORR 81%，其中 CR 14%
🔹 中位 DOR 16.7 个月
🔹 中位 PFS 19.3 个月
🔹 中位 OS 未达到
🔹 ≥3 级治疗相关不良事件：52%；33% 停用 ≥1 种药物
双 ADC 靶向 Trop-2 + Nectin-4 显示出令人印象深刻的早期活性，但关键问题是额外疗效是否足以抵消相比 EV+pembrolizumab 的毒性。
@UroToday @myESMO
330 浏览 · 6 赞 · 3 转发 · 1 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org- Amy@AmyOtto8
@chavarriagaj Challenge is the high CR rate seen with EV +P in EV 302. It’s curious why we don’t see it here. And I like the dual payload approach
来源：Julian Chavarriaga · x.com